ABSTRACT
Lung cancer is the most important cause of death from malignant disease worldwide, and is likely to remain so for many years, given projected estimates for global tobacco consumption. The disease is aggressive, yet presents with symptoms relatively late in its natural history, by which time most tumors have metastasized. This common disease, a major cause of cancer mortality, generally fatal once symptomatic, yet curable if detected early enough, is a prime target for screening.1
